Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-06), Grape King Bio's 3-1 Month Momentum % is -12.16%.
The industry rank for Grape King Bio's 3-1 Month Momentum % or its related term are showing as below:
TPE:1707's 3-1 Month Momentum % is ranked worse than 74.07% of 1022
companies
in the Drug Manufacturers industry
Industry Median: -1.16
vs TPE:1707: -12.16
Grape King Bio (TPE:1707) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Grape King Bio 3-1 Month Momentum % Related Terms
TPE:1707 vs ZTS: 3-1 Month Momentum % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Grape King Bio's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Grape King Bio 3-1 Month Momentum % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Grape King Bio's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Grape King Bio's 3-1 Month Momentum % falls into.
Grape King Bio (TPE:1707) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Grape King Bio (TPE:1707) has a 3-1 Month Momentum % of -12.16% as of Sep. 06, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Grape King Bio and its competitors. According to the industry distribution chart, Grape King Bio ranks #757 out of 1022 companies in the Drug Manufacturers industry, placing it in the top 74.1%.
Is Grape King Bio's 3-1 Month Momentum % too high?
Grape King Bio's current 3-1 Month Momentum % is -12.16%. Based on the distribution chart, Grape King Bio ranks #757 out of 1022 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Grape King Bio has a GF Score™ of 81/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Grape King Bio's 3-1 Month Momentum % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Grape King Bio ranks #757 out of 1022 companies for 3-1 Month Momentum %. This places Grape King Bio in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Drug Manufacturers company?
A good 3-1 Month Momentum % depends on the Drug Manufacturers industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Grape King Bio and its competitors. Grape King Bio's current 3-1 Month Momentum % is -12.16%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grape King Bio stock overvalued right now?
Based on GuruFocus' analysis, Grape King Bio (TPE:1707) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$134.38, compared to a current price of NT$90.50 — trading 32.7% below its estimated fair value. The current 3-1 Month Momentum % is -12.16%. Grape King Bio's overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Grape King Bio (TPE:1707), the current 3-1 Month Momentum % is -12.16% as of Sep. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Grape King Bio (TPE:1707) Overvalued in 2026?
Based on GuruFocus' analysis, Grape King Bio stock appears to be undervalued.
The current stock price of NT$90.50 is trading 32.7% below its estimated GF Value™ of NT$134.38.
GuruFocus considers Grape King Bio to be Significantly Undervalued.
Key valuation signals for TPE:1707:
3-1 Month Momentum %: -12.16%
GF Value™: NT$134.38 vs. price of NT$90.50 (32.7% below fair value)
No single metric tells the full story. See the TPE:1707 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Grape King Bio Ltd is a specialty and generic drug manufacturing company engaged in producing and selling pharmaceutical preparations, patent medicines, liquid tonics, drinks, and healthy food. The company has three segments: MLM (Multi-Level Marketing), which is a direct seller of Pro-partner Inc, including the company's development and manufacturing products for Pro-partner Inc, the Distributors segment includes the company's self-owned brand products, and ODM/OEM (Original Design Manufacturer/Original Equipment Manufacturer) includes ODM/OEM in Taiwan and Shanghai. The group operates in three principal geographical areas - Taiwan, China, and Others, and it derives a majority of its revenue from Taiwan.
81GF Score
Get the complete analysis for TPE:1707
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1707 has been successfully added to your 
